ÂÜÀòÂÒÂ×

Mirna is excited to bring her 15 years of drug development experience to GentiBio in the Sr. Director, Head of Process and Analytical Development role. Prior to joining GentiBio, Mirna contributed to the development of CAR-T cell therapies targeting blood cancers at Juno Therapeutics/Bristol Myers Squibb in process development and CMC team leadership roles. Before transitioning to cell therapy development, Mirna was a process development and technology lead on therapeutic monoclonal antibody programs at Amgen. Mirna holds a B.S. in Chemical Engineering and Ph.D. in Bioengineering from University of Washington.